• 410 Medical

  Participated · Equity · Jul 2026

  410 Medical develops advanced resuscitation technologies centered on its lead product, the LifeFlow infuser, which received FDA clearance in 2016. LifeFlow is used by more than 500 hospitals and EMS agencies and has been used to treat nearly 80,000 patients experiencing conditions like sepsis and hemorrhagic shock. The company was founded in 2013 and is based in North Carolina. In July 2026 410 Medical raised $12 million in growth financing led by Orlando Health Ventures to scale commercial operations and accelerate LifeFlow adoption. The company is also investing in a next-generation LifeFlow device planned for launch in 2027. The financing was supported by a syndicate of hospital and healthcare investors, reflecting continued commercial momentum.

• Vista AI

  Participated · Series B · Jan 2026

  Vista AI provides an AI-driven cardiac MRI automation platform that allows technologists of any experience level to consistently acquire high-quality scans. Its software, already FDA-cleared and commercially deployed, has enabled hospitals such as Brigham and Women’s to open 50 % more scan slots and eliminate a 28-day backlog, while cutting scan times by more than 50 % at Radiology Regional. Headquartered in Palo Alto, the company plans to extend its technology to brain, prostate, and spine imaging, pending additional FDA clearances, and to offer remote scanning services so facilities without in-house experts can perform advanced MRI exams. These expansions aim to create the first comprehensive, fully automated MRI platform and to mitigate the industry’s acute technologist shortage. Vista AI is backed by leading venture funds and prominent U.S. health systems. Following its latest raise, the firm intends to accelerate product development, broaden clinical adoption, and deepen its presence across health networks. The company’s momentum underscores strong demand for solutions that standardize imaging quality while expanding patient access.

• Carta Healthcare

  Participated · Series B · May 2025

  Carta Healthcare provides an AI-powered platform that automates clinical data abstraction and analytics, combining machine learning with deep clinical expertise to extract and structure both structured and unstructured clinical data. Its technology generates actionable insights for health systems and life sciences organizations, streamlining data abstraction processes and reducing labor costs. The company plans to expand its customer footprint—particularly in the life sciences market—and to scale product deployment and operations following its late-2024 acquisition of Realyze Intelligence from UPMC Enterprises. The Realyze Intelligence acquisition added capabilities for rapidly analyzing data and identifying patients who match clinical trials and research studies. Founded in 2017 and headquartered in San Francisco, Carta reports consistent year-over-year growth and says the new capital will support hiring, infrastructure, and expanded market demand. The company’s CFO described Carta as financially healthy and positioned to strengthen its balance sheet and capture market opportunity. Carta Healthcare delivers collection, analysis, and insights into clinical data by providing registry data abstraction, reporting, and analytics to leading health systems. The company combines state-of-the-art technology with a team of experienced clinicians to produce high-quality registry data and associated analytics. By transforming the abstraction process and implementing powerful analytic capabilities, Carta informs data-driven decisions that can improve patient outcomes, reduce data-processing costs, and enable clinicians to spend more time on patient care. The company reports markedly faster data collection, superior data quality, and considerable cost savings for healthcare providers. Carta intends to use the recent funding to scale operations and accelerate product development to make more products accessible to more health systems. The business is focused on enhancing healthcare data processes and analytics to support better patient outcomes and research capabilities. Carta Healthcare provides AI-driven clinical data abstraction technology and services that use natural language processing and machine learning to reduce manual labor in curating trustworthy, actionable datasets. Its platform collects, analyzes, and layers analytic capabilities on clinical data to fuel data-driven healthcare decisions and improve patient care. The company supports the healthcare data registry market by transforming previously manual abstraction processes into automated workflows. Carta plans to use new funding to expand its clinical and technical teams and build new partnerships to make healthcare data more actionable. The company emphasizes making data-driven improvements to care delivery and bringing its solutions to new partners. Carta was founded in 2017 and is headquartered in San Francisco; it announced a recent Series A to accelerate growth.

• HealthSnap

  Participated · Series A · May 2023

  HealthSnap offers an enterprise-grade, EMR-integrated virtual care management platform that combines RPM, CCM, PCM, APCM, AI-augmented clinical workflows, enterprise analytics, reimbursement optimization, and care coordination. The company has embedded AI across care delivery to produce clinician-facing recommendations within clinician-defined protocols and safety guardrails, and launched an AI-augmented APCM solution earlier in the year. HealthSnap supports more than 80,000 active patient programs across 200 health systems and physician organizations, and projects more than 100,000 active patient programs by the end of 2026. Its platform ingests roughly two patient measurements every second, and patients see a 97% reduction in alert frequency by their twelfth month. The company reported significant commercial momentum and financial improvement, including more than fivefold revenue growth over three years, 40% year-over-year revenue growth, and a 47% year-over-year improvement in EBITDA. HealthSnap’s clinical research has shown measurable outcomes, including an average 7.3 mmHg reduction in systolic blood pressure across a cohort of more than 6,500 patients (rising to 16.7 mmHg for Stage 2 hypertensive patients) and retrospective findings of material reductions in total cost of care, hospitalizations, and ED visits among high-acuity Medicare beneficiaries.

• Medical Informatics

  Participated · Series B · Nov 2022

  Medical Informatics Corp (MIC) offers Sickbay™, a vendor-neutral, FDA-cleared platform that archives, aggregates and transforms high-resolution waveform data from disparate bedside devices and unifies it with electronic medical record and other systems. The platform delivers that consolidated data back into clinical care via a web-based interface to enable real-time monitoring, workflow automation and standardized, data-driven care. MIC positions Sickbay to enable remote patient monitoring at scale and to accelerate development and deployment of patient-centered AI. The company says it scaled rapidly during the pandemic and has seen increased demand as hospitals face staffing shortages and shortages of specialty care. MIC will use the new financing to continue fueling rapid growth and to hire deep product specialists and client engagement teams to support long-term strategic partnerships. The company works alongside hospitals and health systems across the U.S. to standardize monitoring infrastructure and consolidate IT spend. Medical Informatics Corp (MIC) offers Sickbay, an FDA-cleared, vendor-neutral platform that continuously captures and processes high-fidelity waveform data from disparate biomedical devices in near real-time. The platform delivers transformed data and context to care teams beyond the bedside to expedite care, reduce patient risk, and support applications such as TeleICUs, waveform delivery to phones, and automated strip charting. Sickbay includes APIs and developer tools so physicians, researchers, and care teams can build their own algorithms and near real-time analytics on accurate waveform data. MIC emphasizes use in complex critical care environments, including ICUs, where continuous waveform data overcomes limits of discrete EMR data. The company is working with partners such as Texas Children’s Hospital to develop alarm management, emergency dispatch apps, and arrest-prediction algorithms for pediatric cardiac patients. MIC announced a recent $11.9 million Series A to accelerate rollout and support implementations and a pipeline of hundreds of additional hospitals.

No current team members are available.